Administration seeks court to nullify lawsuit limiting access to abortion medication
HOWYA DOIN'?
A: The Trump administration has kept relatively quiet on abortion so far, but things took a turn on Monday when Donald Trump's Justice Department asked a federal court to drop a case that could limbo access to abortions nationwide.
M: NPR's Selena Simmons-Duffin has been keeping a close eye on this case for some time now. So, spill the tea, Selena!
S: Well, mate, it's about challenging the Food and Drug Administration's rules for mifepristone, one of the medications used for medication abortion. It's also employed to manage miscarriages. If you're thinking, "Didn't the Supreme Court already dismiss that case?" - you wouldn't be wrong, but here's the kicker. Three states – Missouri, Idaho, and Kansas – have jumped in. These fellas argue that if residents can receive this medication through the mail, they can't impose bans on abortions. So they're bringing this case back, challenging the FDA's decisions on medication abortion once again.
M: So that's what the Trump administration's Justice Department wants to waive?
S: Yep, spot on. The administration made the same argument in a filing on Monday. It's interesting because the Biden Administration's Justice Department had expressed the same stance, and you might not expect much continuity when it comes to abortion between these two administrations.
A: But it doesn't necessarily mean that the Trump administration will be soft on new abortion restrictions this time around. Pondering about the justices he appointed overturning Roe v. Wade, right?
S: Nah, chill there, pal. It doesn't necessarily mean that. However, there are plenty of ways the Trump administration could restrict abortion outside of this court case if they wish. Katie Keith, director of the Georgetown Center for Health Policy, states, "I would say the jury is still out, essentially, of how aggressive the Trump administration will be on medication abortion."
A: She suggests that if they want to restrict access, the FDA could impose more regulations on who can receive this medication and how. However, it remains to be seen if the FDA will take such action.
M: You believe the FDA would do that?
S: It's hard to predict, but mifepristone has been on the market for nearly 25 years and has been deemed safe and effective for ending pregnancies with another medication called misoprostol. The World Health Organization supports its use without direct healthcare provider supervision in the first trimester of pregnancy. If the Trump administration wants to curb access, they could tinker with regulations outside this court case, giving us to wonder how they will maneuver in the upcoming months.
M: Alright, thanks for sharing, Selena.
S: Cheers, mate. Transcript provided by NPR, Copyright NPR.
NPR transcripts are created on a rush deadline by an NPR contractor. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary.
The enrichment data offers some additional context:
The current status of the case challenging the FDA's rules about mifepristone is that the Trump administration's Justice Department has filed a motion to dismiss the lawsuit. This lawsuit was initially brought by anti-abortion groups but was later taken over by the states of Idaho, Kansas, and Missouri after the U.S. Supreme Court ruled that the original plaintiffs lacked standing.[2][5]
The Trump administration is seeking to dismiss the lawsuit for several reasons:
1. Lack of Standing: The DOJ argues that the states lack legal standing to pursue the lawsuit. The administration claims that the states' argument about financial burdens and potential health risks is not sufficient to establish standing.[1][2][4]
2. Venue: The administration argues that the lawsuit was filed in the wrong venue, as the Northern District of Texas is not the proper court for the case. They suggest that even if the states were to file their own lawsuit there, it could not proceed due to lack of venue.[1][4]
3. Statute of Limitations: The DOJ also points out that the states waited too long to challenge the FDA's actions, which were first implemented in 2016 and are subject to a six-year statute of limitations.[1][4]
Despite defending the FDA's current regulations, the Trump administration has not formally announced any new policy on mifepristone access. However, there have been discussions about a safety review of abortion pills.[4]
- The Trump administration's Justice Department has asked a federal court to drop a case challenging the Food and Drug Administration's rules for mifepristone, a medication used for medication abortion and miscarriage management.
- The three states involved in the case, Missouri, Idaho, and Kansas, argue that if residents can receive this medication through the mail, they can't impose bans on abortions.
- The justice department filing mentions that the Biden Administration's Justice Department had expressed the same stance, hinting at potential policy continuity regarding abortion between these two administrations.
- Katie Keith, director of the Georgetown Center for Health Policy, suggests that the Trump administration could restrict access to medication abortion by imposing more regulations on who can receive this medication and how if they wish.
- Mifepristone has been on the market for nearly 25 years and has been deemed safe and effective for ending pregnancies with another medication called misoprostol.
- The Trump administration's move is part of the broader context of abortion politics, with the possibility of the FDA tightening regulations on medication abortion, impacting both men's health and nutrition and women's health and wellness. This development also falls under the umbrella of general news and science.
